Healthcare / Medical Care FacilitiesNYSE
$13.80
+0.01 (+0.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $47.4M · quality 61.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$707M
P/E
N/A
•EV/EBITDA
20.0x
↑ROE
-0.9%
↓Gross Margin
49.0%
↑Debt/Equity
0.94
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.3%
FCF CAGR
-3.4%
FCF margin
6.2%
FCF / Net income
-14.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.06B · net income $-4.6M · FCF $65.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.06B | $1.06B | $1.03B | $1.05B | $1.07B |
| Net Income | $-4.6M | $-4.6M | $-156.2M | $-80.5M | $-40.4M |
| EBITDA | $57.9M | $57.9M | $-83.6M | $-16.5M | $22.5M |
| EPS | — | — | -3.11 | -1.61 | 1.26 |
| Gross Margin | 49.0% | 49.0% | 48.7% | 48.8% | 50.9% |
| Operating Margin | 6.0% | 6.0% | 4.5% | 3.7% | 9.1% |
| Net Margin | -0.4% | -0.4% | -15.1% | -7.7% | -3.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.94 | 0.94 | 1.09 | 0.91 | 0.84 |
| Current Ratio | 1.56 | 1.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $65.8M | $65.8M | $47.4M | $44.9M | $73.0M |
| Returns | |||||
| ROE | -0.9% | -0.9% | -29.8% | -12.0% | -5.4% |
| Valuation | |||||
| P/E | — | — | — | — | 10.00 |
| EV/EBITDA | 19.97 | 19.97 | — | — | 54.60 |
| P/B | 1.31 | 1.31 | 0.75 | 0.73 | 0.84 |
| Growth & Yield | |||||
| Revenue Growth | 2.4% | 2.4% | -1.1% | -2.3% | — |
| EPS Growth | — | — | -93.2% | -227.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+30.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.11 → n/d
Residual
+30.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.